La catena delle opzioni mostra i dati chiave delle opzioni azionarie di 2seventy bio a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per 2seventy bio..

2seventy bio (NASDAQ:TSVT) Azioni, Catena delle Opzioni

2seventy bio

2seventy bio Inc is a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer. The company operates in a single segment, focusing on researching, developing and commercializing potentially transformative treatments for cancer.

2seventy bio Inc

General Motors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>) will end production of its gas-powered Cadillac XT4 SUV at its Fairfax Assembly plant in Kansas in January 2025.
What Happened: The Fairfax plant currently manufactures the Cadillac XT4 and the Chevrolet Malibu. In May, GM said that the production of the Chevrolet Malibu <a href="https://www.benzinga.com/news/24/05/38722473/gm-kicks-one-more-iconic-gas-powered-chevy-car-to-the-curb-as-ev-focus-sharpens" target="_blank" rel="noreferrer noopener">would end in November</a>, Reuters <a href="https://www.detroitnews.com/story/business/autos/general-motors/2024/11/07/gm-ending-cadillac-xt4-production-in-january/76112996007/">reported </a>on Thursday
Following the halt in production in January, the plant will be retooled and production will resume in late 2025 with the next generation of Chevrolet Bolt EVs. The company halted production of the previous generation of Bolt EVs in December 2023. 
GM will invest about $390 million in the retooling process, the company <a href="https://www.benzinga.com/news/24/09/40975105/general-motors-to-lay-off-about-1700-employees-ahead-of-chevrolet-malibu-phase-out-and-re-tooling-fo">said in September</a>. 
Deliveries of the XT4 and the Malibu have been dropping since the start of 2024. While Cadillac XT4 sales in the U.S. dropped 12% in the nine months through the end of September, Malibu sales dropped 16%. 
The company did not immediately respond to <a href="http://pro.benzinga.com">Benzinga&#8217;s</a> request for comment.
Why It Matters: In the third quarter, GM became the second best-seller of EVs in the U.S. after Tesla as the company sold over 32,000 EVs, with the Chevrolet Equinox EV accounting for most of the deliveries.
GM had the longest EV lineup in the U.S. among major players including Tesla in the quarter with eight EV models on sale. 
GM&#8217;s EV sales, however, continue to <a href="https://www.benzinga.com/news/24/11/41736208/gm-crosses-300k-ev-deliveries-in-us-since-2016-but-its-still-over-40-lower-than-teslas-sales-in-the">trail behind Tesla&#8217;s.</a> Tesla sold 166,923 units in the U.S. in the three months, or 6.6% more than Q3 2023.
Check out more of Benzinga&#8217;s Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/11/41803756/xpeng-flying-car-can-be-mastered-in-3-hours-says-company-chairman" target="_blank" rel="noreferrer noopener">XPeng Flying Car Can Be Mastered In 3 Hours, Says Company Chairman</a></li>
</ul>
Photo by Jonathan Weiss on Shutterstock

Equities

News

Markets

Tech

General

GM Reallocates Resources To Focus On EVs: Cadillac XT4 Production To Halt In January After Sales Dropped 12% In 9 Months

NRG Energy, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NRG#NYSE">NRG</a>) will release earnings results for its third quarter, before the <a href="https://www.benzinga.com/quote/nrg/earnings">opening bell on Friday, Nov. 8</a>.
Analysts expect the Houston, Texas-based bank to report quarterly earnings at $2 per share, up from $1.41 per share in the year-ago period. NRG Energy projects to report revenue of $9.38 billion for the recent quarter, compared to $7.95 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
NRG Energy announced it is partnering with Renew Home, a leading virtual power plant (VPP) company to boost its residential VPP capabilities.
NRG Energy shares gained 4.3% to close at $96.40 on Thursday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/TCOM/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul>
<li>Citigroup analyst Ryan Levine maintained a Buy rating and raised the price target from $84 to $100 on Oct. 31. This analyst has an accuracy rate of 67%.</li>
<li>Wells Fargo analyst Neil Kalton maintained an Overweight rating and raised the price target from $120 to $130 on Oct. 30. This analyst has an accuracy rate of 66%.</li>
<li>BMO Capital analyst James Thalacker maintained a Market Perform rating and increased the price target from $90 to $94 on Oct. 29. This analyst has an accuracy rate of 69%.</li>
<li>Guggenheim analyst Shahriar Pourezza maintained a Buy rating and raised the price target from $77 to $118 on Oct. 8. This analyst has an accuracy rate of 66%.</li>
<li>Jefferies analyst Julien Dumoulin-Smith initiated coverage on the stock with a Hold rating and a price target of $78 on Sept. 13. This analyst has an accuracy rate of 68%.</li>
</ul>
Considering buying NRG stock? Here&#8217;s what analysts think:
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/11/41820056/how-to-earn-500-a-month-from-nvidia-stock-after-trump-win">How To Earn $500 A Month From Nvidia Stock After Trump Win</a></li>
</ul>

Earnings

Price Target

Pre-Market Outlook

Analyst Ratings

Trading Ideas

Top Wall Street Forecasters Revamp NRG Energy Price Expectations Ahead Of Q3 Earnings

INFA

Informatica Prices Secondary Offering At $25.50, Permira And Canada Pension Plan Investment Board Offer 16 Million Shares

<ul>
<li>AMC "goes on offense" with plans to expand its Premium Large Format ("PLF"), Extra Large Format ("XLF") and Laser at AMC footprint over the next four to seven years</li>
<li>AMC's Go Plan also includes theatre renovations and seating upgrades at AMC theatres in the United States and ODEON Cinemas in Europe</li>
<li>AMC's Go Plan positions AMC to thrive as the box office recovery gains momentum</li>
</ul>

Reported Earlier, AMC Unveils $1.5 Billion "Go Plan" For Premium Upgrades, Aims To Transform Movie-Going Experience With Expanded IMAX, Dolby, And XL Formats

VMAR

Reported Earlier, Vision Marine Technologies Back In Compliance With Nasdaq Listing Rules

Bloomin&#8217; Brands, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLMN#NASDAQ">BLMN</a>) will release earnings results for its third quarter, before the <a href="https://www.benzinga.com/quote/BLMN/earnings">opening bell on Friday, Nov. 8.</a>
Analysts expect the Tampa, Florida-based company to report quarterly earnings at 20 cents per share, down from 44 cents per share in the year-ago period. Bloomin&#8217; Brands projects to report revenue of $1.04 billion for the quarter, compared to $1.08 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On Aug. 26, Bloomin&#8217; Brands named Michael L. Spanos as Chief Executive Officer.
Bloomin&#8217; Brands shares fell 1.2% to close at $16.78 on Thursday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/BLMN/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul>
<li>B of A Securities analyst Justin Post maintained a Neutral rating and cut the price target from $22 to $19 on Oct. 22. This analyst has an accuracy rate of 85%.</li>
<li>Barclays analyst Jeffrey Bernstein maintained an Overweight rating and slashed the price target from $22 to $20 on Oct. 22. This analyst has an accuracy rate of 64%.</li>
<li>Citigroup analyst Jon Tower maintained a Neutral rating and cut the price target from $22 to $20 on Aug. 19. This analyst has an accuracy rate of 74%.</li>
<li>Deutsche Bank analyst Lauren Silberman maintained a Hold rating and slashed the price target from $26 to $19 on Aug. 7. This analyst has an accuracy rate of 76%.</li>
<li>UBS analyst Dennis Geiger maintained a Neutral rating and cut the price target from $26 to $18 on Aug. 7. This analyst has an accuracy rate of 68%.</li>
</ul>
Considering buying BLMN stock? Here&#8217;s what analysts think:
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/11/41820056/how-to-earn-500-a-month-from-nvidia-stock-after-trump-win">How To Earn $500 A Month From Nvidia Stock After Trump Win</a></li>
</ul>

BLMN

Bloomin' Brands Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Atlanticus Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATLC#NASDAQ">ATLC</a>) reported quarterly earnings of $1.27 per share which beat the analyst consensus estimate of $1.25 by 1.6 percent. This is a 23.3 percent increase over earnings of $1.03 per share from the same period last year. The company reported quarterly sales of $350.954 million which beat the analyst consensus estimate of $341.805 million by 2.68 percent. This is a 19.00 percent increase over sales of $294.907 million the same period last year.

Earnings Beats

ATLC

Atlanticus Holdings Q3 2024 GAAP EPS $1.27 Beats $1.25 Estimate, Sales $350.954M Beat $341.805M Estimate

Telecom Argentina (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEO#NYSE">TEO</a>) reported quarterly sales of $1.046 billion which beat the analyst consensus estimate of $943.022 million by 10.92 percent. This is a 3.59 percent decrease over sales of $1.085 billion the same period last year.

Telecom Argentina Stet - France Telecom S.A.

Telecom Argentina Q3 Sales $1.046B Beat $943.022M Estimate

FFIE

Reported Earlier, Faraday Future Announces Collaboration With JC Sportline, Showcases Two Enhanced FF 91 2.0 Models At SEMA Show

<ul>
<li>FUJI SOFT's advisors, directors, and officers tendered ~90% of their share options</li>
<li>Result means any plan to privatize FUJI SOFT will require KKR's support</li>
</ul>

Reported Earlier, KKR Completes First Tender Offer for FUJI SOFT, Acquiring 33.86% Stake; Plans Second Stage At 110% Premium

Reported Earlier, Osisko Development Moves Closer To Cariboo Gold Project Approval, Awaits BC Ministry's Permit Decisions In Q4 2024

TVTX

Reported Earlier, Travere Therapeutics Prices $125M Public Offering Of 7,812,500 Common Stock At $16/Share

&nbsp;"The top-line results from our Phase 3 WAYPOINT study represent a significant step forward in our commitment to enhancing the lives of those affected by chronic rhinosinusitis with nasal polyps," said&nbsp;Jay Bradner, M.D., executive vice president of Research and Development and chief scientific officer at&nbsp;Amgen. "The data highlight tezepelumab's unique capacity to target multiple inflammatory pathways by acting directly at the epithelium, resulting in meaningful symptom relief that can improve patients' daily experiences."

AMGN

Amgen And AstraZeneca Report Phase 3 Results: Tezspire Meets Both Primary Endpoints In Chronic Rhinosinusitis With Nasal Polyps Study

CRBG

Reported Earlier, Corebridge Financial's Secondary Offering Prices At $31.20/Share, As AIG Moves To Reduce Holdings In Strategic Stock Sale

Sony Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SONY#NYSE">SONY</a>) reported quarterly earnings of $0.32 per share which beat the analyst consensus estimate of $0.27 by 18.52 percent. The company reported quarterly sales of $19.890 billion which beat the analyst consensus estimate of $19.619 billion by 1.38 percent. This is a 1.60 percent increase over sales of $19.577 billion the same period last year.

Sony Group Corporation American Depositary Shares

SONY

Sony Group Q2 2024 GAAP EPS $0.32 Beats $0.27 Estimate, Sales $19.890B Beat $19.619B Estimate

KT Q3 Sales $4.91B Down From $5.10B YoY

Carl Icahn, the renowned billionaire investor, is planning to increase his firm&#8217;s stake in CVR Energy, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVI#NYSE">CVI</a>) while significantly reducing its dividend payout.
What Happened: Icahn Enterprises (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IEP#NASDAQ">IEP</a>), the investment firm controlled by Icahn, is proposing to increase its stake in CVR Energy by over 20%. This move is aimed at capitalizing on what Icahn perceives as an undervalued market, <a href="https://www.wsj.com/finance/investing/icahns-firm-seeks-bigger-stake-in-top-holding-while-slashing-its-own-dividend-26f7f46d?mod=latest_headlines">reported</a> The Wall Street Journal, citing drafts of statements. 
The firm plans to achieve this by purchasing up to 15 million additional shares, raising its holdings to over 81% of CVR&#8217;s shares.
Despite the recent drop in CVR&#8217;s share price, Icahn Enterprises believes the company is undervalued and that shareholders would benefit from a premium cash-out. To fund this transaction and future investments, Icahn Enterprises plans to cut its dividend payout in half.
This is the second time the firm has reduced its dividend since a short-seller report challenged the company&#8217;s valuation and dividend sustainability. Icahn, who owns most of IEP&#8217;s shares, has dismissed the report as misleading.
Icahn Enterprises and CVR Energy did not immediately respond to&nbsp;<a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga</a>'s request for comment.
See Also: <a href="https://www.benzinga.com/markets/equities/24/11/41763411/jeff-bezos-sells-214m-worth-of-amazon-shares-in-latest-stock-move-heres-how-much-he-still-owns?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Jeff Bezos Sells $214M Worth Of Amazon Shares In Latest Stock Move, Here&#8217;s How Much He Still Owns</a>
Why It Matters: Icahn&#8217;s decision to increase his firm&#8217;s stake in CVR Energy comes at a time when the company is facing challenges. CVR Energy recently announced the suspension of its third-quarter dividend, leading to a significant drop in its share price.
Despite these challenges, Icahn remains optimistic about the market&#8217;s potential, citing &#8220;great opportunities for activists&#8221; in undervalued situations.
Earlier in the year, Icahn Enterprises settled charges with the U.S. Securities and Exchange Commission for failing to disclose billions worth of personal loans pledged against Icahn Enterprises' securities. The settlement saw Icahn and his firm pay $1.5 million and $500,000 in civil penalties.
Despite these legal challenges, Icahn has continued to make significant moves in the market. In May, he <a href="https://www.benzinga.com/news/24/05/39117861/carl-icahn-builds-sizable-position-in-caesars-entertainment">built a sizable position in</a> Caesars Entertainment, and in October, he <a href="https://www.benzinga.com/news/24/10/41347078/billionaire-investor-carl-icahn-southwest-gas-amend-cooperation-agreement">amended his cooperation agreement</a> with Southwest Gas. 
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41798981/jim-cramer-calls-trumps-return-to-white-house-a-huge-win-for-the-stock-market?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Jim Cramer Calls Trump&#8217;s Return To White House A &#8216;Huge Win For The Stock Market&#8217;</a></li>
</ul>
Image Via Shutterstock 
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/topic/Kaustubh-Bagalkote" target="_blank" rel="noreferrer noopener">Kaustubh Bagalkote</a>

Carl Icahn Bets Big On CVR While Slashing IEP Dividend In Half

Valley intends to use the net proceeds from this offering for general corporate purposes and for investments in Valley National Bank as regulatory capital.

Macro Economic Events

Econ #s

Economics

Reported Earlier, Valley National Bancorp Prices $400M Public Offering Of 42,780,748 Common Stock At $9.35/Share

The Company intends to use the net proceeds from this offering for working capital and general corporate purposes, which may include capital expenditures, product development and commercialization expenditures, and acquisitions of companies, businesses, technologies and products within and outside the diagnostic services, genomics and consumer products industry.

PRPH

Reported Earlier, ProPhase Labs Prices $3M Public Offering Of 4.17M Common Shares At $0.72/Share

Key Highlights for October 2024 :
<ul>
<li>Bitcoin Production: HIVE mined 117 BTC, marking a 1% increase month-over-month and bringing its HODL portfolio to 2,624 BTC, a 51% increase year-over-year.</li>
<li>Mining Capacity: Maintained an average mining capacity of 5.3 EH/s with fleet efficiency at 22.3 Joules per Terahash (J/TH), reaching a peak hashrate of 5.6 EH/s.</li>
<li>Operational Efficiency: Achieved an average daily production rate of 3.77 BTC, equivalent to 22.1 Bitcoin per Exahash.</li>
<li>Bitcoin Valuation: HIVE's Bitcoin holdings are valued at over $184 million as of October 31, 2024, based on a BTC closing price of approximately $70,215.</li>
</ul>

HIVE

HIVE Digital October 2024 Production Results: Bitcoin Holdings Values At $184M, Mining Capacity Reaches 5.6 EH/s

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on 2seventy bio (TSVT – Research Report), Illumina (ILM...

Analysts Offer Insights on Healthcare Companies: 2seventy bio (TSVT), Illumina (ILMN) and Larimar Therapeutics (LRMR)

2seventy bio, Inc. (TSVT) Q2 2024 Earnings Call Transcript

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Walgreens Boots Alliance (WBA – Research Report), 2seventy bio (T...

Analysts' Opinions Are Mixed on These Healthcare Stocks: Walgreens Boots Alliance (WBA), 2seventy bio (TSVT) and Repare Therapeutics (RPTX)

2seventy bio ( ($TSVT) ) has issued an announcement. 2seventy bio, Inc. has announced the termination of enrollment in the Phase 3 KarMMa-9 study o...

2seventy bio Halts KarMMa-9 Study, Forecasts Strong Abecma Sales

Bristol Myers, 2seventy bio halt enrollment in Abecma late-stage trial

In a report released today, Vikram Purohit from Morgan Stanley maintained a Hold rating on 2seventy bio (TSVT – Research Report), with a price targ...

Hold Rating on 2seventy bio Amidst Strategic Shifts and Enrollment Challenges

Daina Graybosch, an analyst from Leerink Partners, reiterated the Buy rating on 2seventy bio (TSVT – Research Report). The associated price target ...

Buy Rating Affirmed for 2seventy bio Despite Trial Setback: Niche Market Strategy and Safety Profile Underpin Positive Outlook

TD Cowen analyst Yaron Werber maintained a Hold rating on 2seventy bio (TSVT – Research Report) today. The company's shares closed last Friday at $...

TD Cowen Sticks to Its Hold Rating for 2seventy bio (TSVT)

Bristol-Myers raises outlook ahead of consensus after Q3 beat

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Arvinas Holding Company (ARVN – Research Report), 2s...

Analysts Are Bullish on These Healthcare Stocks: Arvinas Holding Company (ARVN), 2seventy bio (TSVT)

ARVN

ILMN

LEGN

LRMR

RPTX

TSVT

VKTX

Press Releases

TSVT INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into 2seventy bio, Inc. and Encourages Investors to Contact the Firm

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 2seventy bio, Inc. - TSVT

2seventy bio to Report Third Quarter 2024 Financial Results and Participate in Upcoming Investor Conference

Abeona Therapeutics

Acrivon Therapeutics, Inc. - Common Stock

Acrivon Therapeutics

Amarin Corporation plc - American Depositary Shares, each representing one Ordinary Share

Comments

2seventy bio

2seventy bio (TSVT) Opzioni

2seventy bio (NASDAQ:TSVT) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO